246 related articles for article (PubMed ID: 36926025)
1. The link between bone-derived factors osteocalcin, fibroblast growth factor 23, sclerostin, lipocalin 2 and tumor bone metastasis.
Martiniakova M; Mondockova V; Biro R; Kovacova V; Babikova M; Zemanova N; Ciernikova S; Omelka R
Front Endocrinol (Lausanne); 2023; 14():1113547. PubMed ID: 36926025
[TBL] [Abstract][Full Text] [Related]
2. Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?
Arai Y; Takeuchi H; Oishi K; Yoshida O
Prostate; 1992; 20(3):169-77. PubMed ID: 1374180
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Hyperglycemic microenvironment compromises the homeostasis of communication between the bone-brain axis by the epigenetic repression of the osteocalcin receptor, Gpr158 in the hippocampus.
Patricia da Silva E; da Silva Feltran G; Alexandre Alcântara Dos Santos S; Cardoso de Oliveira R; Assis RIF; Antônio Justulin Junior L; Carleto Andia D; Zambuzzi WF; Latini A; Foganholi da Silva RA
Brain Res; 2023 Mar; 1803():148234. PubMed ID: 36634900
[TBL] [Abstract][Full Text] [Related]
5. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis.
Koeneman KS; Kao C; Ko SC; Yang L; Wada Y; Kallmes DF; Gillenwater JY; Zhau HE; Chung LW; Gardner TA
World J Urol; 2000 Apr; 18(2):102-10. PubMed ID: 10854144
[TBL] [Abstract][Full Text] [Related]
6. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.
Koeneman KS; Yeung F; Chung LW
Prostate; 1999 Jun; 39(4):246-61. PubMed ID: 10344214
[TBL] [Abstract][Full Text] [Related]
7. Human prostate cancer progression models and therapeutic intervention.
Chung LW; Kao C; Sikes RA; Zhau HE
Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
[TBL] [Abstract][Full Text] [Related]
8. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
Koizumi M; Yonese J; Fukui I; Ogata E
J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
[TBL] [Abstract][Full Text] [Related]
9. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
[TBL] [Abstract][Full Text] [Related]
10. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of serum osteocalcin in patients with bone metastasis of breast cancer].
Suzuki S; Nomizu T; Nihei M; Rokkaku Y; Kimijima I; Tsuchiya A; Abe R
Nihon Gan Chiryo Gakkai Shi; 1989 Oct; 24(10):2386-93. PubMed ID: 2614177
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
13. Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis.
Carlson N; Mortensen OH; Axelsen M; Pedersen RS; Heaf JG
Blood Purif; 2017; 44(2):122-128. PubMed ID: 28554171
[TBL] [Abstract][Full Text] [Related]
14. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M
J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572
[TBL] [Abstract][Full Text] [Related]
15. [Clinical evaluation on serum osteocalcin in advanced prostate cancer patients].
Abe H; Nakagami YJ; Ito H; Ikeda K; Oka F; Niwa N
Hinyokika Kiyo; 1991 Aug; 37(8):877-80. PubMed ID: 1720275
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of osteocalcin during the metastatic progression of prostate cancer.
Gardner TA; Lee SJ; Lee SD; Li X; Shirakawa T; Kwon DD; Park RY; Ahn KY; Jung C
Oncol Rep; 2009 Apr; 21(4):903-8. PubMed ID: 19287987
[TBL] [Abstract][Full Text] [Related]
17. Bone, a Secondary Growth Site of Breast and Prostate Carcinomas: Role of Osteocytes.
Maroni P; Bendinelli P
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32640686
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer.
Zhu M; Liu C; Li S; Zhang S; Yao Q; Song Q
Sci Rep; 2017 Sep; 7(1):11399. PubMed ID: 28900298
[TBL] [Abstract][Full Text] [Related]
19. Correlations between serum concentration of three bone-derived factors and obesity and visceral fat accumulation in a cohort of middle aged men and women.
Xu Y; Ma X; Pan X; He X; Xiao Y; Bao Y
Cardiovasc Diabetol; 2018 Nov; 17(1):143. PubMed ID: 30424752
[TBL] [Abstract][Full Text] [Related]
20. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
